SB1035 amends Virginia’s controlled-substances and practitioner-administration statute, § 54.1-3408, to expand and clarify who may dispense, possess, and administer opioid antagonists, especially naloxone, when acting under a prescriber’s order or standing protocol. The bill’s core change is to expressly allow a person acting on behalf of an organization that serves people at risk of opioid overdose, or that provides naloxone training, to dispense naloxone or another opioid antagonist under a standing order and Board of Pharmacy protocols. If the product is an injectable formulation, the organization’s agent must obtain Department of Behavioral Health and Developmental Services authorization to train on needle/syringe use and a controlled substance registration from the Board of Pharmacy, which may not charge a fee for that registration.
The bill also preserves and restates broad existing authority for many other categories of trained personnel to administer medications under protocols, including school employees, health department staff, restaurant employees, higher education employees, outdoor education staff, behavioral health providers, pharmacists, athletic trainers, nurses, dentists, dialysis technicians, and others. In addition to naloxone, the statute continues to cover epinephrine, albuterol, insulin, glucagon, vaccines, topical medications, and other specified drugs in schools, health care settings, public accommodations, and emergency situations. The bill also keeps the general rule that any person may administer naloxone or another opioid antagonist to someone believed to be experiencing a life-threatening opioid overdose.
SB1035’s main legal impact is on § 54.1-3408 of the Code of Virginia, where it adds a new subsection specifically addressing organizational dispensing of naloxone and reinforces the existing framework for delegated medication administration. It affects prescribers, pharmacists, community organizations, overdose-prevention programs, and people trained to distribute naloxone, while leaving in place the Board of Pharmacy and Department of Health protocol authority and recordkeeping requirements. The bill does not create a new standalone program; rather, it broadens and clarifies who may participate in overdose-reversal access under existing public-health and pharmacy rules.
The overall sentiment reflected in the voting history is strongly supportive and largely bipartisan. The bill moved through the Senate and House with overwhelming margins, including unanimous or near-unanimous committee and floor votes, indicating broad agreement with expanding naloxone access and simplifying distribution through organizations. The lack of recorded opposition in the Senate and only minimal opposition in the House suggests the measure was viewed as a public-health and overdose-response bill with little controversy.
The main point of contention, to the extent one exists, is the scope of delegated dispensing authority and the safeguards around injectable naloxone. The bill requires additional authorization and controlled-substance registration for organizations dispensing injectable formulations with needles or syringes, reflecting concern about training, disposal, and regulatory oversight. More broadly, the statute’s many delegated-administration provisions could raise questions about training, supervision, and liability, but the bill text and vote history do not show significant public disagreement over those issues.
SB1035 amends § 54.1-3408 of the Code of Virginia to expressly authorize a person acting on behalf of an organization serving people at risk of opioid overdose, or providing naloxone training, to dispense naloxone or another opioid antagonist under a standing order and Board of Pharmacy protocols. It also requires extra authorization and controlled-substance registration for injectable naloxone with a hypodermic needle or syringe, while preserving the ability of any person to administer naloxone in an overdose emergency. The bill leaves in place and restates a wide range of existing delegated-medication authorities for schools, health care settings, behavioral health providers, restaurants, higher education, athletic trainers, dentists, dialysis facilities, and others.
The bill appears to have been received very positively and with broad bipartisan support. It passed Senate committee and floor votes unanimously or nearly unanimously, and it also passed the House by a wide margin, indicating little organized opposition. The voting pattern suggests lawmakers generally viewed the measure as a practical public-health and overdose-prevention expansion rather than a controversial policy change.
The principal policy issue is how far to extend delegated authority to dispense naloxone outside traditional clinical settings. Supporters appear to favor easier community access through organizations that train and serve at-risk populations, while the bill’s safeguards for injectable naloxone show an effort to address concerns about training, safe handling, disposal, and controlled-substance oversight. Any broader concerns about delegation, supervision, and recordkeeping are largely addressed through existing Board of Pharmacy and Department of Health protocols, and the vote history shows little visible disagreement.